#ESMO26 Can we preserve the bladder with EV + P in MIBC? @tompowles1 presented the TiP: EV-209, a phase II trial exploring bladder preservation without planned RC or RT:
📌N≈240, global, single-arm study
📌 Patients eligible for but declining radical cystectomy
📌 EV+P for 4 cycles, followed by MRI/CT, cystoscopy with biopsy/TURBT, and urine cytology
📌 Patients achieving cCR continue treatment (up to 9 EV and 17 pembrolizumab cycles)
📌 Co-primary endpoints: cCR rate and 2-year bladder-intact EFS among responders
📌 Exploratory ctDNA/utDNA MRD analyses
@UroToday @myESMO
355 views · 5 likes · 3 reposts · 0 replies
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgSTARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEfficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study
https://esmocongress.esmo.orgUpdated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.orgSource: Julian Chavarriaga · x.com